Group 1 - The 2025 European Society for Medical Oncology (ESMO) annual meeting held in Berlin is recognized as one of the most influential oncology conferences globally, showcasing significant breakthroughs in research data from Chinese pharmaceutical companies [1] - The event is seen as a key catalyst for the international expansion of Chinese innovative drugs, with high-quality data disclosure being crucial for international collaboration [1][3] - A total of 2,929 abstracts were presented at the conference, with 448 from Chinese companies, indicating a strong presence and recognition of China's innovation capabilities [2] Group 2 - Chinese pharmaceutical companies showcased their innovative capabilities through clinical data presentations, with 23 studies selected for the latest breakthrough abstracts (LBA), a significant increase from 7 in 2024 [2] - Notable companies like Jiangsu Hengrui Medicine Co., Ltd. presented multiple LBA studies, highlighting their commitment to international research and development strategies [2] - The conference served as a foundation for further international market expansion, with positive clinical data acting as a catalyst for business development (BD) collaborations with major international pharmaceutical companies [3] Group 3 - The total value of overseas BD transactions for Chinese innovative drugs reached $387 billion in the first nine months of the year, nearing the total for the entire previous year [3] - Recent BD agreements, such as the one between Hansoh Pharmaceutical Group and Roche, indicate ongoing interest and activity in the sector [4] - Industry experts predict that while the total transaction value may not reach new highs, the overall number of BD transactions will remain substantial, driven by ongoing innovation and supportive policies [4][5]